Later-Line Treatment for mCRC: Regorafenib or TAS-102?



Howard S. Hochster, MD, FACP: For patients who have received all the standard drugs—this could be third line or it could be fourth line, depending on how you use your anti-EGF antibodies—today we’re looking at a couple of drugs that are approved in that setting. One is regorafenib and the other is TAS-102.

So these are pretty different drugs with pretty different toxicity profiles. The regorafenib is a multikinase tyrosine kinase inhibitor, so it has a lot of the TKI type toxicities of hand-foot syndrome, rash, and fatigue. I think it’s a difficult drug to give to colon cancer patients if they’re already beginning to have systemic symptoms and they aren’t too robust. I think for the more robust patients, it’s probably worthwhile giving them a try of this drug. There is certainly a tail on the benefit curve such that some people really can stay on it for 6 to 12 months and really benefit from it. That would be maybe up to 20% of patients.…Particularly with some of the new dosing information from the ACCRU trial, I think that it’s probably easier to give the drug starting at 50% dose and then escalating, so I’ve been doing that a little bit more.

The TAS-102 is antimetabolite. That’s a little different than 5-fluorouracil [5-FU] but certainly seems to be beneficial in patients who have gotten a lot of 5-FU previously. And I think there are a lot of opportunities to combine that drug with irinotecan or with oxaliplatin. We’re presenting a poster, here at the GI [Gastrointestinal Cancers Symposium] ASCO [American Society of Oncology] meeting, with my colleagues from Yale of a study that we did with TAS-OX, TAS-102 with oxaliplatin. That’s tolerated pretty well. I think there are more opportunities to eventually move TAS-102 into earlier-line therapies.

Transcript Edited for Clarity

Related Videos
Amin Nassar, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Pashtoon Murtaza Kasi, MD, MS
Michael Iglesia, MD, PhD
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Jin Qian, PhD
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer